Citi analyst Joanne Wuensch raised the firm’s price target on Abbott to $127 from $119 and keeps a Buy rating on the shares. The analyst calls Q2 “another wild ride” for the medical technology sector. The earnings prints brought “several eye-opening and frankly shocking deliveries, changes to guidance, and stock price reactions,” the analyst tells investors in a research note. Citi expects an “interesting” September broker season, and looks for updated management commentary on patient volumes, capital equipment, and China. It reiterated its top picks of Boston Scientific (BSX), GE HealthCare (GEHC), and Insulet (PODD), looking for acceleration moving through the remainder of 2024 and into 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott announces implantation of AVEIR DR pacemaker system in Canada
- Stifel sees ‘unexpected diabetes tech marriage’ as negative for DexCom, others
- Medtronic announces FDA approval for Simplera CGM and partnership with Abbott
- Abbott announces global partnership with Medtronic
- Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin
Questions or Comments about the article? Write to editor@tipranks.com